{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-044034","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.666570+00:00","generated_at":"2026-06-01T21:27:34.131286+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bluejay Diagnostics increases authorized shares from 7.5M to 50M; shareholders approve reverse stock split up to 1:10","bullets":["Authorized shares of common stock increased from 7,500,000 to 50,000,000 via amendment filed May 14, 2024.","Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-10; board to decide final ratio and timing.","Directors Donald Chase, Neil Dey, Svetlana Dey, Fred Zeidman, Gary Gemignani, and Douglas Wurth re-elected.","Ratification of Wolf & Company, P.C. as independent auditor for FY2024 approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-044034","json":"https://secwatch.observer/filing/0001213900-24-044034.json","markdown":"https://secwatch.observer/filing/0001213900-24-044034.md","text":"https://secwatch.observer/filing/0001213900-24-044034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/ea020636401-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:27:34.131286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07b28d4d3cce60f812370222feb01670e74f8b33","claim":"Bluejay Diagnostics, Inc.: Increased authorized common shares from 7,500,000 to 50,000,000 via amendment to certificate of incorporation (effective 2024-05-14).","evidence_excerpt":"On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","confidence":0.9},{"claim_id":"2a04baf953ddd8812f00cb43b1360bbf9dcce743","claim":"Bluejay Diagnostics, Inc. shareholders approved Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm at the 2024-05-14 meeting.","evidence_excerpt":"Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","confidence":0.9},{"claim_id":"b90d72d3d85c39721516b04f2248c25156ca650f","claim":"Bluejay Diagnostics, Inc. shareholders approved Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2024-05-14 meeting.","evidence_excerpt":"Proposal 2. Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock - The Company’s stockholders approved and adopted an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of the Company’s common stock.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","confidence":0.9},{"claim_id":"c18b006103b1f92dbc41431f3c0124c43315061c","claim":"Bluejay Diagnostics, Inc. shareholders approved Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split at the 2024-05-14 meeting.","evidence_excerpt":"Proposal 3. Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split - The Company’s stockholders approved and adopted an amendment to the Company’s certificate of incorporation to effect a reverse stock split of all of the Company’s outstanding shares of common stock by one of several fixed ratios between 1-for-2 and 1-for-10 (the “Reverse Stock Split”), with the final decision of whether to proceed with the Reverse Stock Split, the effective time of the Reverse Stock Split, and the exact ratio of the Reverse Stock Split to be determined in the future by the Company’s board of directors, in its sole discretion and without further action by the Company’s stockholders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","confidence":0.9},{"claim_id":"c5dfd89f6b5f13d00f02616168e0ef685a765547","claim":"Bluejay Diagnostics, Inc. shareholders approved Election of directors at the 2024-05-14 meeting.","evidence_excerpt":"Proposal 1. Election of Directors - The Company’s stockholders re-elected each of Donald Chase, Neil Dey, Svetlana Dey, Fred Zeidman, Gary Gemignani and Douglas Wurth to serve as directors until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001690820-26-000039","ticker":"CVNA","company_name":"CARVANA CO.","filed_at":"2026-05-06T23:59:59+00:00","headline":"Carvana stockholders approve 5-for-1 stock split, adopt new 2026 incentive plan","event_type":"other_material","sec_items":["5.02","5.03","5.07","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001690820-26-000039","json":"https://secwatch.observer/filing/0001690820-26-000039.json","markdown":"https://secwatch.observer/filing/0001690820-26-000039.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690820/000169082026000039/0001690820-26-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690820/000169082026000039/cvna-20260505.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","comparable_excerpt":"At the Annual Meeting, the Company's stockholders approved an amendment (the \"Amendment\") to the Company's Amended and Restated Certificate of Incorporation to effect a five-for-one forward stock split of the Company's Class A common stock and Class B common stock (the \"Stock Split\") and to proportionately increase the number of authorized shares of Class A common stock and Class B common stock (the \"Authorized Share Increase\").","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1690820/000169082026000039/0001690820-26-000039-index.htm"}},{"accession":"0001178913-26-002393","ticker":"SLXN","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-05T23:59:59+00:00","headline":"Silexion shareholders approve 50M share increase, expanded equity plan, and 1-for-10 reverse split","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002393","json":"https://secwatch.observer/filing/0001178913-26-002393.json","markdown":"https://secwatch.observer/filing/0001178913-26-002393.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/zk2635202.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","comparable_excerpt":"At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm"}},{"accession":"0001891101-26-000032","ticker":"BRCC","company_name":"BRC Inc.","filed_at":"2026-06-02T10:18:43+00:00","headline":"BRCC regains NYSE minimum share price compliance; reverse split approved but not needed","event_type":"other_material","sec_items":["5.07","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001891101-26-000032","json":"https://secwatch.observer/filing/0001891101-26-000032.json","markdown":"https://secwatch.observer/filing/0001891101-26-000032.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1891101/000189110126000032/0001891101-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1891101/000189110126000032/brcc-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","comparable_excerpt":"Proposal 2. Ratification of the Appointment of the Independent Registered Public Accountants The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: For Against Abstain Broker Non-Votes 144,256,280 1,491,239 195,288 0","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1891101/000189110126000032/0001891101-26-000032-index.htm"}},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","comparable_excerpt":"On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001213900-26-063486","ticker":"MDAI","company_name":"Spectral AI, Inc.","filed_at":"2026-06-01T20:01:42+00:00","headline":"Spectral AI gets FDA clearance for DeepView burn indication; targets first commercial sales by year-end 2026","event_type":"other_material","sec_items":["5.07","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063486","json":"https://secwatch.observer/filing/0001213900-26-063486.json","markdown":"https://secwatch.observer/filing/0001213900-26-063486.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026063486/0001213900-26-063486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026063486/ea0292962-8k_spectral.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","comparable_excerpt":"The stockholders voted at the Annual Meeting to approve the Hudson Bay Proposal. Votes For Votes Against Abstentions Broker Non-Votes 9,272,055 1,838,069 134,311 6,023,135","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026063486/0001213900-26-063486-index.htm"}},{"accession":"0001829126-26-004879","ticker":"SAGU","company_name":"Shreya Acquisition Group","filed_at":"2026-05-11T23:59:59+00:00","headline":"Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004879","json":"https://secwatch.observer/filing/0001829126-26-004879.json","markdown":"https://secwatch.observer/filing/0001829126-26-004879.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/shreyaacq_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","comparable_excerpt":"On May 6, 2026, and in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm"}},{"accession":"0001287032-26-000174","ticker":"PSEC","company_name":"PROSPECT CAPITAL CORP","filed_at":"2026-05-08T23:59:59+00:00","headline":"Prospect Capital enters $400M at-the-market preferred stock offering; reclassifies 16M common shares","event_type":"other_material","sec_items":["1.01","3.03","5.03","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001287032-26-000174","json":"https://secwatch.observer/filing/0001287032-26-000174.json","markdown":"https://secwatch.observer/filing/0001287032-26-000174.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287032/000128703226000174/0001287032-26-000174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287032/000128703226000174/psec-20260508.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","comparable_excerpt":"On May 8, 2026, in connection with the Offering, the Company filed Articles Supplementary (the “Articles Supplementary”) with the State Department of Assessments and Taxation of Maryland (“SDAT”), reclassifying and designating 16,000,000 authorized and unissued shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), into shares of Series A Preferred Stock.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1287032/000128703226000174/0001287032-26-000174-index.htm"}},{"accession":"0001628280-26-032901","ticker":"HAWK","company_name":"HawkEye 360, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"HawkEye 360 closes IPO on May 8; files amended charter and bylaws","event_type":"other_material","sec_items":["5.03","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-032901","json":"https://secwatch.observer/filing/0001628280-26-032901.json","markdown":"https://secwatch.observer/filing/0001628280-26-032901.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750704/000162828026032901/0001628280-26-032901-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750704/000162828026032901/hawkeye360-closing8xk.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm","comparable_excerpt":"Effective as of May 8, 2026, the Company adopted Amended and Restated Bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1750704/000162828026032901/0001628280-26-032901-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}